An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chon, Young Eun | - |
dc.contributor.author | Kim, Dong Joon | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Bae, Si Hyun | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Heo, Jeong | - |
dc.contributor.author | Jang, Jeong Won | - |
dc.contributor.author | Lee, Byung Seok | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Kim, Kang Mo | - |
dc.contributor.author | Chung, Woo Jin | - |
dc.contributor.author | Choi, Moon Seok | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Yoon, Ki Tae | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Han, Kwang-Hyub | - |
dc.contributor.author | Suk, Ki Tae | - |
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Jang, Byoung Kuk | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.date.accessioned | 2021-08-02T17:26:29Z | - |
dc.date.available | 2021-08-02T17:26:29Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2016-04 | - |
dc.identifier.issn | 0025-7974 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/23844 | - |
dc.description.abstract | Currently, limited data are available regarding the efficacy and safety of pegylated interferon alpha-2a (PEG-IFN α-2a) in Korean patients with chronic hepatitis B (CHB), in whom hepatitis B virus (HBV) genotype C is the most common type. We collected data from 439 patients (HBeAg positive, n=349; HBeAg negative, n=90) with CHB who were treated with PEG-IFN α-2a as a first-line therapy from 18 institutions. Treatment responses at the end of treatment (ET) and at 6 months posttreatment (PT6) were compared between the patients who were treated for 24 weeks versus 48 weeks, and adverse events (AEs) were evaluated. In HBeAg-positive patients, those who received PEG-IFN α-2a for 48 weeks showed significantly higher HBV DNA suppression (HBV DNA<2000IU/mL) than those who were treated for 24 weeks (48 weeks vs 24 weeks; at ET, 44.4% vs 36.7%, P=0.035; at PT6, 35.9% vs 13.3%, P=0.035). The HBeAg seroconversion rate at ET was 18.1% in 48-week treatment group, which is significantly higher than the 2.2% (P<0.001) that was seen in 24-week treatment group. This finding also continued at PT6 (29.0% vs 10.0%, P<0.001). Following 48 weeks of treatment in HBeAg-negative patients, HBV DNA suppression at ET was higher than in HBeAg-positive patients (87.8% vs 44.4%). AEs were typical of those associated with PEG-IFN alpha-2a. In naive Korean HBeAg-positive CHB patients treated with PEG-IFN alpha-2a, higher rates of HBV DNA suppression and HBeAg seroconversion were achieved in the 48-week treatment group than in the 24-week treatment group without additional risk of AEs. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | - |
dc.title | An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) TRACES Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.1097/MD.0000000000003026 | - |
dc.identifier.scopusid | 2-s2.0-84964612656 | - |
dc.identifier.wosid | 000375257000004 | - |
dc.identifier.bibliographicCitation | MEDICINE, v.95, no.14, pp.1 - 8 | - |
dc.relation.isPartOf | MEDICINE | - |
dc.citation.title | MEDICINE | - |
dc.citation.volume | 95 | - |
dc.citation.number | 14 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | TENOFOVIR DISOPROXIL FUMARATE | - |
dc.subject.keywordPlus | CONTINUOUS ENTECAVIR THERAPY | - |
dc.subject.keywordPlus | ON-TREATMENT PREDICTION | - |
dc.subject.keywordPlus | PEGINTERFERON ALPHA-2A | - |
dc.subject.keywordPlus | SUSTAINED RESPONSE | - |
dc.subject.keywordPlus | STOPPING RULE | - |
dc.subject.keywordPlus | HBV DNA | - |
dc.subject.keywordPlus | HBEAG | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.identifier.url | https://journals.lww.com/md-journal/Fulltext/2016/04050/An_Observational,_Multicenter,_Cohort_Study.4.aspx | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.